P62/SQSTM1 (Sequestosome 1) Drug Discovery Landscape & Assay Solutions
- By admin
- 05 Aug 2026
- Comments
Market Intelligence, Clinical Progress, and High-Purity Reagents for Autophagy and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for P62/SQSTM1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | P62/SQSTM1 Full-Length & Domain Proteins (PB1, UBA, ZZ). High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View SQSTM1 Products |
| Gene Delivery | SQSTM1 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines. | View SQSTM1 Products |
| Mutant Library | SQSTM1 Domain Mutants (K7A/D69A, ΔUBA, LIR mutants). For mechanism validation. | View SQSTM1 Products |
| Benchmark Ab | Anti-P62/SQSTM1, recombinant positive control for western blot and IP. | View P62/SQSTM1 Products |
| Validator | SQSTM1 siRNA Set. For knockdown verification. | View SQSTM1 Products |
| Related Target A | MAP1LC3A (LC3). Autophagy pathway partner and direct binding interactor. | View MAP1LC3A Products |
| Related Target B | KEAP1. Oxidative stress pathway partner interacting with p62. | View KEAP1 Products |
| Related Target C | NBR1 (Neighbor of BRCA1). Synergistic autophagy receptor, forms hetero-oligomers with P62. | View NBR1 Products |
| Related Target D | OPTN (Optineurin). Alternative autophagy receptor, functional redundancy analysis. | View OPTN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction Validation | High-purity (>95%) recombinant p62 for precise SPR/BLI affinity testing. |
| Mutant Targeting (e.g., Paget's Disease) | Disease-relevant mutant variants strictly verified by theoretical MW. |
| Lack of Reliable Cellular Controls | Validated siRNA included for strict specificity checks in knockdown models. |
| PB1 Domain Oligomerization Disruption | Purified PB1 Domain (aa 1-122) with verified K7A/D69A mutant available for oligomerization-deficient controls. |
| Ubiquitin Binding (UBA Domain) Selectivity | UBA Domain (aa 377-436) with ΔUBA truncation mutant for negative control assays. |
| LC3 Interaction (LIR Motif) Validation | Full-length LIR-mutant (D337A/D338A) and WT proteins for comparative binding studies. |
| Cross-reactivity with Autophagy Adaptors | NBR1 and OPTN ortholog proteins available for selectivity screening. |
| Aggregation/Phase Separation Studies | High-concentration (>5mg/mL), low-endotoxin proteins suitable for LLPS assays. |
Live P62/SQSTM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for P62/SQSTM1 therapeutics is intensifying, with major players shifting focus from traditional inhibitors to targeted protein degradation (PROTACs) and selective autophagy modulators. As an intracellular hub linking ubiquitin to the autophagy machinery (LC3), P62/SQSTM1 is critical in both neurodegenerative diseases (like ALS and FTD) and oncology. As first-generation therapies reach the clinic, the next wave of R&D is targeting selective disruption of the p62-Keap1 or p62-LC3 axes.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTACs / Degraders | Various Biotech | Neurodegeneration (ALS), Oncology | Ternary Complex Assays (Need high-purity recombinant proteins) |
| Small Molecules | Academic / Pharma Consortia | Paget's Disease, Cancer | PPI Inhibition Assays (Keap1/LC3 binding validation) |
| Gene Therapy | Emerging Innovators | Rare Neurodegenerative | Functional Rescue (Need accurate ORF clones) |
P62/SQSTM1 Functional Domains and Key Mutations
Based on UniProt Q13501, P62/SQSTM1 contains key functional domains:
- PB1 domain: Involved in self-oligomerization and interaction with other PB1-containing proteins.
- UBA domain: Binds ubiquitin, linking ubiquitinated cargo to the autophagy machinery.
Key mutations associated with disease (FTDALS3 and other disorders):
- rs1554162295 (in FTDALS3)
- rs141502868
- rs200396166 (in FTDALS3)
These mutations are critical for studying disease mechanisms and developing targeted therapies.